Dengue Literature Review

Wiki State and Gap Analysis 2026-04-13

10 min read

Wiki State and Gap Analysis — 2026-04-13

Curator-directed synthesis of current wiki coverage and research priorities. Supersedes Wiki State and Gap Analysis 2026-04-12.

Current Wiki State

16 sources | 64 pages total as of 2026-04-13.

Page Inventory

CategoryCountPages
Sources16See index
Entities11DENV-1/2/3/4, FcγRIIa Receptor, Aedes aegypti, Aedes albopictus, NS1 Protein, E Protein, CYD-TDV, Wolbachia
Concepts17Post-Dengue Syndrome, Autoimmunity in Dengue, ADE, Asymptomatic Dengue Infection, Antinuclear Antibodies, Infection-Triggered Autoimmunity, NS1 Molecular Mimicry in Dengue, T Cell Responses in Dengue, NK Cell Responses in Dengue, Type I Interferon Response in Dengue, Viraemia, Dengue Pathophysiology, Dengue Clinical Classification, Dengue Vaccine Candidates, Original Antigenic Sin, Dengue Neurological Complications, Secondary Dengue Infection
Methods11PRNT, ELISA Inhibition Method, FcγRIIa Genotyping, Indirect Immunofluorescence ANA Test, Single-Cell RNA Sequencing, V(D)J Sequencing, qRT-PCR, RT-PCR, NS1 Antigen Detection, IgM-IgG Serology ELISA, Line Immunoassay ANA
Geography4Cuba, Thailand, Taiwan, India
Analyses4This page, Wiki State 2026-04-12, Reading Plan, Notable Findings, ANA and Dengue — A Literature Review
Meta1state.md

What Changed Since 2026-04-12

The wiki grew from 9 sources / 27 pages to 16 sources / 64 pages — more than doubling — through seven ingests:

SourceKey Contribution
Lin2006 - Autoimmune Pathogenesis in Dengue Virus InfectionNS1 molecular mimicry mechanism; anti-platelet IgM; endothelial apoptosis + NF-κB pathways
Lin2011 - Molecular Mimicry Virus Host Dengue PathogenesisNS1 C-terminal domain (aa 311–352); PDI/vimentin/HSP60/ATP synthase β targets; WGNGCG coagulation motif; anti-prM
Guzman2016 - Dengue InfectionComprehensive review; global burden; direct sNS1 TLR4/endothelial/thrombin/glycocalyx mechanisms; vaccine pipeline; vector biology
Shih2023 - Autoimmune Disease Risk After DengueLarge population-based refutation of broad autoimmune risk claim; ADEM only; 51.4% misclassification rate identified
Wan2012 - Autoimmunity in Dengue PathogenesisCapstone NCKU review; autoantibody kinetics; LYRIC/RGD/capsid mimicry; intrinsic ADE–autoimmunity link
Chatterjee2024 - ANA Detection in Dengue KolkataFirst HEp-2 IIFA measurement in acute dengue: 54.8% IIFA, 18.5% LIA; non-specific majority; MCTD/myositis signals
Sungnak2025 - Distinct Immune Responses Asymptomatic Symptomatic DenguescRNA-seq + V(D)J in Thailand DENFREE cohort; CD8 TEM exhaustion in DHF; public BCR clonotype absent at convalescence; 120-target autoantibody panel negative

The two top priorities from the 2026-04-12 analysis have been addressed:

  • ✅ NS1 molecular mimicry papers — three sources (Lin2006, Lin2011, Wan2012) plus Guzman2016 now fully evidence this mechanism
  • ✅ ANA specificity in dengue — Chatterjee2024 provides HEp-2 IIFA + LIA data, answering which specificities are elevated and how many are non-specific

One priority from 2026-04-12 remains unresolved:

Today, a comprehensive ANA literature review was completed:

Research Thread Summary

Primary Thread: Autoimmunity in Dengue / ANA Dynamics

Status: Substantially developed. The ANA literature review now provides a complete synthesis. The central narrative is stable:

  1. Dengue produces a massive acute ANA spike (~55% by HEp-2 IIFA), far exceeding healthy-population baselines (~13–16% at 1:80) and the generic viral-infection rate (~21.7% by narrower ELISA)
  2. ~66% of this spike is non-specific — not corresponding to disease-associated autoantibody specificities on LIA
  3. NS1 molecular mimicry is the dengue-specific mechanism for immune-mediated platelet lysis and endothelial damage, but its established targets (PDI, vimentin, HSP60, ATP synthase β) are surface proteins, not nuclear antigens — leaving the mechanism of the HEp-2-positive nuclear ANA unexplained by mimicry alone; epitope spreading is the leading candidate
  4. Bystander activation is insufficient to explain the ANA elevation (COVID-19 ICU null finding, Johnson2022)
  5. At the population level, dengue does not broadly elevate clinical SARD incidence (Shih2023); only ADEM is robustly elevated, and only in the first month
  6. ANA persists at 2 years post-dengue in symptomatic patients (Garcia2009), but the substrate incompatibility (rat liver vs. HEp-2) makes the acute-to-chronic trajectory unresolvable from current data

What remains open:

  • The acute-to-chronic trajectory of ANA (1, 3, 6-month time points on HEp-2 not yet measured in any dengue source)
  • Whether NS1 shares structural homology with nuclear antigens (not yet tested in the literature covered)
  • Whether the MCTD and myositis signals in Chatterjee2024 represent genuine disease risk or LIA noise
  • Whether FcγRIIa genotype predicts ANA rate/persistence, as the IC-persistence model predicts

Secondary Thread: Asymptomatic vs. Symptomatic Dengue

Status: Begun but thin. Sungnak2025 is the strongest entry — scRNA-seq in the Thailand DENFREE cohort identifies CD8 TEM effector (asymptomatic) vs. exhausted (DHF) phenotypes, NK FcεRIγ signature, and a public BCR clonotype present only in symptomatic disease and absent at convalescence. Garcia2010 from Cuba provides the FcγRIIa genotype data. Only 2 dedicated sources; the thread needs population-level incidence data and broader immunological coverage.

Coverage Gaps and Thin Areas

1. Post-Dengue Syndrome — Still Only 1 Dedicated Source

Garcia2009 remains the sole paper in this wiki directly measuring post-dengue sequelae in a follow-up cohort. Guzman2016 provides secondary coverage from a review. The core claim that autoimmune markers persist at 2 years rests on n=26 symptomatic Cuban adults, single epidemic, no contemporaneous control group for the ANA measurement.

What to look for:

  • Any prospective longitudinal cohort following dengue patients ≥6 months post-recovery with standardised symptom assessment — PubMed: “post-dengue sequelae longitudinal” OR “dengue convalescence symptoms”
  • Seet et al. 2007 (Emerg Infect Dis) — Singapore post-dengue cohort; cognitive and fatigue sequelae; frequently cited in this area
  • Any cohort with ANA measurement at multiple time points (acute + convalescence + 6 months) — this is the single most important methodological gap in the ANA thread

2. ANA Trajectory — The Core Unresolvable Gap

The most clinically significant open question is: does the acute HEp-2 IIFA spike (~55%) persist or resolve, and at what rate? No source in this wiki measures dengue ANA at more than one time point using HEp-2. Garcia2009 uses rat liver (incompatible substrate; 2-year time point only). This is structurally a single missing experiment.

What to look for:

  • Any study measuring serial ANA by HEp-2 IIFA in dengue patients at acute, convalescent, and post-convalescent time points — may be in Asian rheumatology journals
  • Studies examining autoantibody persistence after arboviral infections as a proxy (chikungunya has a better-documented post-acute arthropathy literature)

3. FcγRIIa — Contradiction Still Unresolved

The paradox flagged in the 2026-04-12 analysis remains: Garcia2010 identifies FcγRIIa-HH as a risk genotype for symptomatic dengue, on the rationale that HH has higher IgG1 binding affinity enabling more efficient ADE. But Bruhns et al. 2009 (Blood) — not yet in this wiki — shows FcγRIIa-RR has higher binding affinity for IgG3, which would predict the opposite. The FcγRIIa Receptor and Antibody-Dependent Enhancement pages flag this contradiction but cannot resolve it without Bruhns.

Priority: medium. The contradiction does not affect the ANA narrative but matters for the ADE mechanism and for the asymptomatic/symptomatic thread.

4. Geography — Four Countries, No Regional Overview Pages

Coverage: Cuba (3 sources), Taiwan (2), Thailand (1), India (1). No regional overview pages for Southeast Asia, Latin America/Caribbean, or South Asia. No coverage of the largest dengue-burden countries: Indonesia, Philippines, Brazil, Vietnam, Bangladesh.

What to look for:

  • Bhatt et al. 2013 (Nature) — the canonical global burden paper; would anchor a global geography overview and populate an Americas/Southeast Asia page simultaneously
  • Any country-specific seroprevalence or epidemiology paper for a high-burden country not yet in the wiki
  • Southeast Asia regional page could be created using Guzman2016’s epidemiology section as a starting point (currently cited but no dedicated page)

5. Thin Entity Pages (Single Source)

EntitySource CountSuggestion
DENV-11Any serotype-comparative paper would add both DENV-1 and other serotypes simultaneously
DENV-31As above
E Protein2Lin2011 + Guzman2016 cover the WGNGCG motif — a flavivirus E protein review would expand this substantially
Aedes albopictus1A vector biology / range expansion paper (albopictus is globalising)
CYD-TDV1Sridhar et al. 2018 (NEJM) — the serostatus-stratified efficacy paper; critical for the vaccine thread
Wolbachia1Any Wolbachia field trial paper (Moreira et al. or WMP data)

6. Missing Concept Pages (Referenced But Absent)

ConceptReferenced InPriority
Cytokine StormGuzman2016, multipleMedium — relevant to both pathophysiology and ADE
Cross-Reactive AntibodiesJohnson2022, Lin2006Medium — distinct from NS1 mimicry in scope
Herd ImmunityGuzman2016Low — not central to current research threads
Dengue Haemorrhagic FeverGuzman2016, Lin2006Medium — the clinical endpoint for most mechanism work; currently covered in Dengue Clinical Classification but deserves its own page

7. Diagnostics — Better Than Before, but Uneven

The method pages are now less sparse than in the 2026-04-12 state. NS1 Antigen Detection has 3 sources; IIFA and LIA are documented. However:

  • RT-PCR has only 1 source; no paper covering the viraemia window / PCR sensitivity timeline
  • IgM-IgG serology has only 1 source; no coverage of the primary vs. secondary infection serology distinction (which affects ADE interpretation)
  • No paper on the WHO Dengue Diagnostic Guidelines or head-to-head diagnostic comparisons

8. Vaccine and Vector Biology — Almost Empty

The Dengue Vaccine Candidates concept page has 3 sources, but all coverage comes from Guzman2016’s comprehensive review — no dedicated vaccine efficacy papers. Vector biology coverage (Aedes aegypti with 5 sources) is better, but relies on Guzman2016 for most content.

Priority: Low relative to the autoimmunity thread, unless the curator’s focus shifts.

What the ANA Thread Has and Has Not Answered

QuestionStatusNotes
Is dengue ANA elevated above healthy-population baseline?✅ EstablishedBoth acutely (54.8% IIFA, Chatterjee2024) and at 2 years (23.1% rat liver, Garcia2009) — both exceed reference ranges
What proportion of dengue ANA is disease-specific?✅ Established~34% of IIFA-positives confirmed by LIA; ~66% non-specific (Chatterjee2024)
Which specific autoantibodies are elevated?⚠️ PartialLIA shows MCTD and myositis-associated antibodies (Chatterjee2024); but wide CIs and small n; no dengue-specific HEp-2 pattern characterised
What mechanism drives nuclear ANA in dengue?⚠️ InferredNS1 mimicry targets surface proteins, not nuclear antigens → epitope spreading is the leading candidate; not directly demonstrated
Does dengue-associated ANA resolve or persist?❌ OpenThe acute-to-chronic trajectory on HEp-2 is absent; only Garcia2009’s 2-year rat liver data exists; substrate gap makes the question unresolvable from current data
Does dengue ANA lead to clinical autoimmune disease?✅ Established (population level)Shih2023 (n=63,814): no broad SARD elevation; only ADEM in month 1
Do host factors (FcγRIIa, sex) predict ANA?⚠️ IndirectFcγRIIa-HH associated with post-dengue sequelae (Garcia2009); sex effect on ANA is established in healthy populations; no study directly links FcγRIIa genotype to ANA rate

Priority Order for Next Ingests

PriorityPaper / TopicGap Addressed
1Longitudinal dengue cohort with serial ANA (HEp-2, multiple time points)The single most important missing experiment — resolves the acute-to-chronic trajectory
2Second post-dengue sequelae cohort (e.g. Seet 2007, Singapore)Replicates Garcia2009 in a different country/serotype; makes the post-dengue syndrome claim generalisable
3Bhatt et al. 2013 (Nature) — global dengue burdenAnchors global geography; fills the largest geographic gap
4Sridhar et al. 2018 (NEJM) — CYD-TDV serostatus and efficacyThe most important vaccine paper; the CYD-TDV entity page is a stub
5Bruhns et al. 2009 (Blood) — FcγRIIa binding affinitiesResolves the IgG3/RR paradox flagged in FcγRIIa Receptor and ADE pages
6Serotype-comparative dengue paper (incidence or severity by DENV-1/2/3/4)Strengthens thin DENV-1 and DENV-3 entity pages simultaneously

Sources

All 16 sources in the wiki inform this analysis. Key sources for gap assessment:

Graph View

Backlinks